ETON Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Eton Pharmaceuticals (ETON) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available for investment. The company has strong growth prospects, positive analyst sentiment, and recent FDA approvals that enhance its competitive position. Despite some overbought technical indicators, the long-term outlook and catalysts make this a compelling investment opportunity.
The stock exhibits bullish technical indicators with MACD positively expanding, RSI at 86.827 indicating overbought conditions, and SMA_5 > SMA_20 > SMA_200 confirming an upward trend. Key resistance levels are at 20.249 and 21.35, with support at 18.467 and 16.685.
FDA approval for Desmoda therapy, which enhances competitive edge and opens new revenue streams.
Acquisition of U.S. rights to Hemangeol, an FDA-approved treatment with strong sales potential.
Strong revenue growth of 82.8% YoY in Q4 2025 and projected revenues exceeding $110 million by
Positive analyst sentiment with raised price targets to $30 and $37, citing accretive deals and market expansion.
RSI indicates overbought conditions, suggesting potential short-term pullback.
Net income dropped significantly YoY in Q4 2025, reflecting potential profitability concerns.
In Q4 2025, revenue increased by 82.72% YoY to $21.28M, while net income dropped by -347.99% YoY to $1.48M. EPS improved significantly by 750% YoY to -0.17, and gross margin increased to 61.56%, up 10.72% YoY. The company projects revenues exceeding $110M by 2026 with an adjusted EBITDA margin of at least 30%.
Analysts maintain a Buy rating with raised price targets of $30 and $37. They cite the acquisition of Hemangeol and FDA approval for Desmoda as key drivers of growth and market expansion.
